Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...
Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of Opdivo and Yervoy, this time in newly diagnosed liver cancer. PD-1 inhibitor ...
There's nothing quite like the pairing of Thanksgiving and the NFL. It's honestly one of my favorite holidays for the simple fact that all we have to do is sit back, watch football, and stuff our ...
Full-screen Always-On Display functionality has been expanded to remain active throughout the day without requiring screen taps or lift gestures. Users can enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results